A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2026 and March 31, 2025 is as follows (in thousands):


Three Months Ended March 31, 2026	Contingent Consideration Liability Related to the Acquisition of:
	Arkis (1)		Derma Sciences (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2026	$	6,299	$	350	19,400		26,049
Payment	—		—		—		—
Change in fair value of contingent consideration liabilities	9		(2)		(1,300)		(1,293)
Balance as of March 31, 2026	6,308		348		18,100		24,756

Short-Term - Accrued expenses and other liabilities	$	—	$	—	$	18,100	$	18,100
Long-Term - Other liabilities	6,308		348		—		6,656
Total	6,308		348		18,100		24,756


Three Months Ended March 31, 2025	Contingent Consideration Liability Related to the Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2025	$	12,968	$	2,686	$	3	$	54,000	69,657
Payment	(5,000)		—		—		—		(5,000)
Change in fair value of contingent consideration liabilities	(812)		50		—		600		(162)
Balance as of March 31, 2025	$	7,156	$	2,736	$	3	$	54,600	64,495

Short-Term - Accrued expenses and other liabilities	$	3,598	$	—	$	—	$	35,000	$	38,598
Long-Term - Other liabilities	3,558		2,736		3		19,600		25,897
Total	7,156		2,736		3		54,600		64,495